299 related articles for article (PubMed ID: 20449049)
1. Inhibition of protein-protein interactions using designed molecules.
Wilson AJ
Chem Soc Rev; 2009 Dec; 38(12):3289-300. PubMed ID: 20449049
[TBL] [Abstract][Full Text] [Related]
2. Protein-protein interactions as targets for small-molecule therapeutics in cancer.
White AW; Westwell AD; Brahemi G
Expert Rev Mol Med; 2008 Mar; 10():e8. PubMed ID: 18353193
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of α-helix-mediated protein-protein interactions using designed molecules.
Azzarito V; Long K; Murphy NS; Wilson AJ
Nat Chem; 2013 Mar; 5(3):161-73. PubMed ID: 23422557
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations.
Buchwald P
IUBMB Life; 2010 Oct; 62(10):724-31. PubMed ID: 20979208
[TBL] [Abstract][Full Text] [Related]
5. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Rowinsky EK
J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
[TBL] [Abstract][Full Text] [Related]
6. Emerging classes of protein-protein interaction inhibitors and new tools for their development.
Pagliaro L; Felding J; Audouze K; Nielsen SJ; Terry RB; Krog-Jensen C; Butcher S
Curr Opin Chem Biol; 2004 Aug; 8(4):442-9. PubMed ID: 15288255
[TBL] [Abstract][Full Text] [Related]
7. Disruption of protein-protein interactions: towards new targets for chemotherapy.
Loregian A; Palù G
J Cell Physiol; 2005 Sep; 204(3):750-62. PubMed ID: 15880642
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting protein-protein interactions using designed molecules.
Zhao L; Chmielewski J
Curr Opin Struct Biol; 2005 Feb; 15(1):31-4. PubMed ID: 15718130
[TBL] [Abstract][Full Text] [Related]
9. Are MAP kinases drug targets? Yes, but difficult ones.
Margutti S; Laufer SA
ChemMedChem; 2007 Aug; 2(8):1116-40. PubMed ID: 17541990
[TBL] [Abstract][Full Text] [Related]
10. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
11. Strategies for targeting protein-protein interactions with synthetic agents.
Yin H; Hamilton AD
Angew Chem Int Ed Engl; 2005 Jul; 44(27):4130-63. PubMed ID: 15954154
[TBL] [Abstract][Full Text] [Related]
12. Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I).
Morelli X; Bourgeas R; Roche P
Curr Opin Chem Biol; 2011 Aug; 15(4):475-81. PubMed ID: 21684802
[TBL] [Abstract][Full Text] [Related]
13. Antitumour drug design: DNA-binding ligands, which inhibit the topoisomerase I.
Pindur U; Lemster T
Pharmazie; 1998 Feb; 53(2):79-86. PubMed ID: 9540103
[TBL] [Abstract][Full Text] [Related]
14. Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors.
Burke TR; Yao ZJ; Liu DG; Voigt J; Gao Y
Biopolymers; 2001; 60(1):32-44. PubMed ID: 11376431
[TBL] [Abstract][Full Text] [Related]
15. Chemical approaches to reversible protein phosphorylation.
Cole PA; Courtney AD; Shen K; Zhang Z; Qiao Y; Lu W; Williams DM
Acc Chem Res; 2003 Jun; 36(6):444-52. PubMed ID: 12809531
[TBL] [Abstract][Full Text] [Related]
16. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
17. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
18. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors.
Gohlke H; Klebe G
Angew Chem Int Ed Engl; 2002 Aug; 41(15):2644-76. PubMed ID: 12203463
[TBL] [Abstract][Full Text] [Related]
19. Modulation of protein-protein interactions with small organic molecules.
Berg T
Angew Chem Int Ed Engl; 2003 Jun; 42(22):2462-81. PubMed ID: 12800163
[TBL] [Abstract][Full Text] [Related]
20. Protein-protein interactions as targets for antiviral chemotherapy.
Loregian A; Marsden HS; Palù G
Rev Med Virol; 2002; 12(4):239-62. PubMed ID: 12125015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
